Chimerix (CMRX)
(Delayed Data from NSDQ)
$0.86 USD
-0.02 (-1.72%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $0.86 +0.01 (0.58%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Brokerage Reports
Chimerix, Inc. [CMRX]
Reports for Purchase
Showing records 21 - 40 ( 120 total )
Company: Chimerix, Inc.
Industry: Medical - Products
Initial Takeaways for Days 1-3 of ASCO 2023; Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Chimerix, Inc.
Industry: Medical - Products
Company: Chimerix, Inc.
Industry: Medical - Products
1Q23 Results; Phase 3 ACTION Study Efficacy Data in Early-2025
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Chimerix, Inc.
Industry: Medical - Products
Company: Chimerix, Inc.
Industry: Medical - Products
Biotechnology- Roundup for 2023 AACR Meeting
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Chimerix, Inc.
Industry: Medical - Products
Biotechnology -AACR 2023 Abstract Roundup For Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Chimerix, Inc.
Industry: Medical - Products
4Q22 Results; Phase 3 ACTION Study Enrolling in the U.S.; Encouraging Response Observed in ONC206 Trial
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Chimerix, Inc.
Industry: Medical - Products
Company: Chimerix, Inc.
Industry: Medical - Products
ONC201 Update and Workforce Reduction Announced
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Chimerix, Inc.
Industry: Medical - Products
Company: Chimerix, Inc.
Industry: Medical - Products
Company: Chimerix, Inc.
Industry: Medical - Products
Company: Chimerix, Inc.
Industry: Medical - Products
3Q22 Results; Phase 3 ACTION Study for ONC201 Expected to Initiate in 4Q22
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Chimerix, Inc.
Industry: Medical - Products
Closing of Tembexa Deal With Emergent Biosolutions Announced
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Chimerix, Inc.
Industry: Medical - Products
Tembexa Contract For U.S. Stockpile Signed; Upfront Payment From Partner Increased
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Chimerix, Inc.
Industry: Medical - Products
Company: Chimerix, Inc.
Industry: Medical - Products
Company: Chimerix, Inc.
Industry: Medical - Products
Company: Chimerix, Inc.
Industry: Medical - Products
2Q22 Results; Phase 3 ONC201 Study Could Start Before YE22; Still Waiting for BARDA Stockpile Contract for Tembexa
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E